Clinical Trial

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

Name: AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer — clinical trial record (NCT07617337)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a first-in-human, Phase I, open-label, multicenter, multinational study, designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of AQUA07 when administered as single agent and in combination with lorlatinib in patients with ALK positive non-small cell lung cancer.

Trial Details

NCT Number	NCT07617337
Lead Sponsor	Chugai Pharmaceutical
Conditions	ALK Positive Non-small Cell Lung Cancer
Enrollment	102 participants
Start Date	2026-07-31
Primary Completion	2030-08-31 (estimated)
Study Completion	2030-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-01